Speakers: Dr. Keyue Ding and Dr. Hugh Walker |
|
Cost-effectiveness and Cost-utility Analysis Accompanying Clinical Trials |
An Introduction to Health Economics |
| Presented by Dr. Keyue Ding | Presented by Dr. Hugh Walker |
There is a difference between efficacy and effectiveness measures. Efficacy refers to the performance of a health technology under controlled circumstances, often in the context of randomized controlled trials (RCTs). Administered according to a strict written protocol by research oriented clinicians, trial participants are often selected according to restrictive inclusion and exclusion criteria, then encouraged to comply with treatment, and monitored with care. These trials may be conducted in specialized centres, such as teaching hospitals. In contrast, effectiveness refers to the performance of a technology in the “real world” (i.e., routine use in clinical practice), with a variety of providers using the technology as they deem appropriate for a broad heterogeneous group of patients who are usually less well informed, less likely to be screened or diagnosed correctly, less compliant, and subject to co-morbid conditions and treatments that are excluded in the original efficacy trials. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. The conduct of clinical trials is changing (www.trialstransformation.org). Biostatisticians need to be ready to change the way trials are conducted or, at least, be aware of the new ways that trial data are going to be used. Workshop Abstract Evidence-based medicine is concerned with the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients. Increasingly, health care providers are being asked to weigh economic evidence alongside clinical evidence when making decisions about the care of their patients. Decisions about funding new therapies may also be affected by trade-offs between efficacy and cost. Cost-effectiveness and cost-utility analysis utilizing clinical trial data provide high-quality economic evidence. This session will: * Familiarize participants with common statistical issues in the analysis of cost and efficacy data * Introduce issues arising in the application to randomized trials * Identify common mistakes * Outline preferred analytic approaches to assess relevant issues in cost-effectiveness and cost-utility analyses Participants will see a completed case study with discussion of salient points which arose in real clinical trial data. Hands-on experience with a similar analysis will be obtained using simulated data, since confidentiality precludes the use of real trial data. A reference list will be provided to assist further self-directed professional development. |
Increasingly, …, economic evaluations are being used to inform decisions about other health care technologies, such as vaccines, devices, medical and surgical procedures, disease prevention and screening activities, health promotion activities, and health care delivery initiatives such as telemedicine. Such technologies refer not only to individual products but also to strategies for the management or treatment of a condition. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Workshop Abstract This session takes the viewpoint of the service provider faced with choosing between competing products and technologies to provide the services in its portfolio. The complex array of available products and technologies, used individually or in combination, must be evaluated to deliver the most effective services to the right (sub) population at an affordable cost. The session will: * Introduce major current and future issues in the Economics of Health, particularly resource allocation, sustainability and value for money * Introduce the tools of simulation and optimization for use in evaluating system performance and policy alternatives in the management of the Canadian health system * Provide participants with hands on experience in using small simulation and optimization models with examples of:
|
Please be advised that Workshop capacity is limited to 120 participants and there is no on-site registration. However, payment on site is permitted for registered participants. |
|